{"id":"NCT00996216","sponsor":"GlaxoSmithKline","briefTitle":"Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390","officialTitle":"An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2009-10-16","resultsPosted":"2013-12-06","lastUpdate":"2013-12-06"},"enrollment":27,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Eltrombopag","otherNames":["Promacta"]},{"type":"DRUG","name":"Antiviral therapy","otherNames":[]}],"arms":[{"label":"Open-label eltrombopag","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1","timeFrame":"From the start of investigational product up to the start of antiviral therapy (up to 9 weeks; median of 21 days)","effectByArm":[{"arm":"Eltrombopag","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":15},"locations":{"siteCount":28,"countries":["United States","Australia","Canada","France","Germany","Greece","Italy","Pakistan","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Nausea","Headache","Pyrexia","Anaemia","Leukopenia"]}}